Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

The synthetic peptide P111-136 derived from the C-terminal domain of heparin affin regulatory peptide inhibits tumour growth of prostate cancer PC-3 cells

Authors: Yamina Hamma-Kourbali, Oya Bermek, Isabelle Bernard-Pierrot, Racha Karaky, Dominique Martel-Renoir, Sophie Frechault, José Courty, Jean Delbé

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Heparin affin regulatory peptide (HARP), also called pleiotrophin, is a heparin-binding, secreted factor that is overexpressed in several tumours and associated to tumour growth, angiogenesis and metastasis. The C-terminus part of HARP composed of amino acids 111 to 136 is particularly involved in its biological activities and we previously established that a synthetic peptide composed of the same amino acids (P111-136) was capable of inhibiting the biological activities of HARP. Here we evaluate the ability of P111-136 to inhibit in vitro and in vivo the growth of a human tumour cell line PC-3 which possess an HARP autocrine loop.

Methods

A total lysate of PC-3 cells was incubated with biotinylated P111-136 and pulled down for the presence of the HARP receptors in Western blot. In vitro, the P111-136 effect on HARP autocrine loop in PC-3 cells was determined by colony formation in soft agar. In vivo, PC-3 cells were inoculated in the flank of athymic nude mice. Animals were treated with P111-136 (5 mg/kg/day) for 25 days. Tumour volume was evaluated during the treatment. After the animal sacrifice, the tumour apoptosis and associated angiogenesis were evaluated by immunohistochemistry. In vivo anti-angiogenic effect was confirmed using a mouse Matrigel™ plug assay.

Results

Using pull down experiments, we identified the HARP receptors RPTPβ/ζ, ALK and nucleolin as P111-136 binding proteins. In vitro, P111-136 inhibits dose-dependently PC-3 cell colony formation. Treatment with P111-136 inhibits significantly the PC-3 tumour growth in the xenograft model as well as tumour angiogenesis. The angiostatic effect of P111-136 on HARP was also confirmed using an in vivo Matrigel™ plug assay in mice

Conclusions

Our results demonstrate that P111-136 strongly inhibits the mitogenic effect of HARP on in vitro and in vivo growth of PC-3 cells. This inhibition could be linked to a direct or indirect binding of this peptide to the HARP receptors (ALK, RPTPβ/ζ, nucleolin). In vivo, the P111-136 treatment significantly inhibits both the PC-3 tumour growth and the associated angiogenesis. Thus, P111-136 may be considered as an interesting pharmacological tool to interfere with tumour growth that has now to be evaluated in other cancer types.
Appendix
Available only for authorised users
Literature
1.
Cunha GR, Donjacour A: Stromal-epithelial interactions in normal and abnormal prostatic development. Prog Clin Biol Res. 1987, 239: 251-272.PubMed
2.
Courty J, Milhiet PE, Delbe J, Caruelle D, Barritault D: Heparin-Affin Regulatory Peptide, HARP. Springer. 2000
3.
Russell PJ, Bennett S, Stricker P: Growth factor involvement in progression of prostate cancer. Clin Chem. 1998, 44 (4): 705-723.PubMed
4.
Muramatsu T: Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem (Tokyo). 2002, 132 (3): 359-371.CrossRef
5.
Pufe T, Bartscher M, Petersen W, Tillmann B, Mentlein R: Expression of pleiotrophin, an embryonic growth and differentiation factor, in rheumatoid arthritis. Arthritis Rheum. 2003, 48 (3): 660-667. 10.1002/art.10839.CrossRefPubMed
6.
Heroult M, Bernard-Pierrot I, Delbe J, Hamma-Kourbali Y, Katsoris P, Barritault D, Papadimitriou E, Plouet J, Courty J: Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. Oncogene. 2004, 23 (9): 1745-1753. 10.1038/sj.onc.1206879.CrossRefPubMed
7.
Chauhan AK, Li YS, Deuel TF: Pleiotrophin transforms NIH 3T3 cells and induces tumors in nude mice. Proceedings of the National Academy of Sciences of the United States of America. 1993, 90 (2): 679-682. 10.1073/pnas.90.2.679.CrossRefPubMedPubMedCentral
8.
Fang W, Hartmann N, Chow DT, Riegel AT, Wellstein A: Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. Journal of Biological Chemistry. 1992, 267 (36): 25889-25897.PubMed
9.
Soulie P, Heroult M, Bernard-Pierrot I, Caruelle D, Oglobine J, Barritault D, Courty J: Correlation of elevated plasma levels of two structurally related growth factors, heparin affin regulatory peptide and midkine, in advanced solid tumor patients. Cancer Detect Prev. 2004, 28 (5): 319-324. 10.1016/j.cdp.2004.03.004.CrossRefPubMed
10.
Souttou B, Juhl H, Hackenbruck J, Rockseisen M, Klomp HJ, Raulais D, Vigny M, Wellstein A: Relationship between serum concentrations of the growth factor pleiotrophin and pleiotrophin-positive tumors. J Natl Cancer Inst. 1998, 90 (19): 1468-1473. 10.1093/jnci/90.19.1468.CrossRefPubMed
11.
Vacherot F, Caruelle D, Chopin D, Gil-Diez S, Barritault D, Caruelle JP, Courty J: Involvement of heparin affin regulatory peptide in human prostate cancer. Prostate. 1999, 38 (2): 126-136. 10.1002/(SICI)1097-0045(19990201)38:2<126::AID-PROS6>3.0.CO;2-C.CrossRefPubMed
12.
Hatziapostolou M, Delbe J, Katsoris P, Polytarchou C, Courty J, Papadimitriou E: Heparin affin regulatory peptide is a key player in prostate cancer cell growth and angiogenicity. Prostate. 2005, 65 (2): 151-158. 10.1002/pros.20270.CrossRefPubMed
13.
Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, Caughey DJ, Wen D, Karavanov A, Riegel AT, et al: Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem. 2001, 276 (20): 16772-16779. 10.1074/jbc.M010660200.CrossRefPubMed
14.
Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994, 263 (5151): 1281-1284. 10.1126/science.8122112.CrossRefPubMed
15.
Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, Mori S, Ratzkin B, Yamamoto T: Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene. 1997, 14 (4): 439-449. 10.1038/sj.onc.1200849.CrossRefPubMed
16.
Peria FM, Neder L, Marie SK, Rosemberg S, Oba-Shinjo SM, Colli BO, Gabbai AA, Malheiros SM, Zago MA, Panepucci RA, et al: Pleiotrophin expression in astrocytic and oligodendroglial tumors and it's correlation with histological diagnosis, microvascular density, cellular proliferation and overall survival. J Neurooncol. 2007, 84 (3): 255-261. 10.1007/s11060-007-9379-2.CrossRefPubMed
17.
Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A: Pleiotrophin signaling through anaplastic lymphoma kinase (ALK) is rate- limiting for glioblastoma growth. J Biol Chem. 2002, 23: 23-
18.
Maeda N, Noda M: Involvement of receptor-like protein tyrosine phosphatase zeta/RPTP beta and its ligand pleiotrophin/heparin-binding growth-associated molecule (HB-GAM) in neuronal migration. J Cell Biol. 1998, 142 (1): 203-216. 10.1083/jcb.142.1.203.CrossRefPubMedPubMedCentral
19.
Polykratis A, Katsoris P, Courty J, Papadimitriou E: Characterization of heparin affin regulatory peptide signaling in human endothelial cells. J Biol Chem. 2005, 280 (23): 22454-22461. 10.1074/jbc.M414407200.CrossRefPubMed
20.
Meng K, Rodriguez-Pena A, Dimitrov T, Chen W, Yamin M, Noda M, Deuel TF: Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta. Proc Natl Acad Sci USA. 2000, 97 (6): 2603-2608. 10.1073/pnas.020487997.CrossRefPubMedPubMedCentral
21.
Pariser H, Ezquerra L, Herradon G, Perez-Pinera P, Deuel TF: Fyn is a downstream target of the pleiotrophin/receptor protein tyrosine phosphatase beta/zeta-signaling pathway: regulation of tyrosine phosphorylation of Fyn by pleiotrophin. Biochem Biophys Res Commun. 2005, 332 (3): 664-669. 10.1016/j.bbrc.2005.05.007.CrossRefPubMed
22.
Pariser H, Herradon G, Ezquerra L, Perez-Pinera P, Deuel TF: Pleiotrophin regulates serine phosphorylation and the cellular distribution of beta-adducin through activation of protein kinase C. Proc Natl Acad Sci USA. 2005, 102 (35): 12407-12412. 10.1073/pnas.0505901102.CrossRefPubMedPubMedCentral
23.
Tamura H, Fukada M, Fujikawa A, Noda M: Protein tyrosine phosphatase receptor type Z is involved in hippocampus-dependent memory formation through dephosphorylation at Y1105 on p190 RhoGAP. Neurosci Lett. 2006, 399 (1-2): 33-38. 10.1016/j.neulet.2006.01.045.CrossRefPubMed
24.
Perez-Pinera P, Zhang W, Chang Y, Vega JA, Deuel TF: Anaplastic Lymphoma Kinase Is Activated Through the Pleiotrophin/Receptor Protein-tyrosine Phosphatase beta/{zeta} Signaling Pathway: An Alternative Mechanism Of Receptor Tyrosine Kinase Activation. J Biol Chem. 2007, 282 (39): 28683-28690. 10.1074/jbc.M704505200.CrossRefPubMed
25.
Bernard-Pierrot I, Delbe J, Caruelle D, Barritault D, Courty J, Milhiet PE: The lysine-rich C-terminal tail of heparin affin regulatory peptide is required for mitogenic and tumor formation activities. J Biol Chem. 2001, 276 (15): 12228-12234. 10.1074/jbc.M010913200.CrossRefPubMed
26.
Bernard-Pierrot I, Delbe J, Rouet V, Vigny M, Kerros ME, Caruelle D, Raulais D, Barritault D, Courty J, Milhiet PE: Dominant negative effectors of heparin affin regulatory peptide (HARP) angiogenic and transforming activities. J Biol Chem. 2002, 277 (35): 32071-32077. 10.1074/jbc.M202747200.CrossRefPubMed
27.
Hamma-Kourbali Y, Bernard-Pierrot I, Heroult M, Dalle S, Caruelle D, Milhiet PE, Fernig DG, Delbe J, Courty J: Inhibition of the mitogenic, angiogenic and tumorigenic activities of pleiotrophin by a synthetic peptide corresponding to its C-thrombospondin repeat-I domain. J Cell Physiol. 2008, 214 (1): 250-259. 10.1002/jcp.21191.CrossRefPubMed
28.
Dos Santos C, Karaky R, Renoir D, Hamma-Kourbali Y, Albanese P, Gobbo E, Griscelli F, Opolon P, Dalle S, Perricaudet M, et al: Antitumorigenic effects of a mutant of the heparin affin regulatory peptide on the U87 MG glioblastoma cell line. Int J Cancer. 2010, 127 (5): 1038-1051.CrossRefPubMed
29.
Bermek O, Diamantopoulou Z, Polykratis A, Dos Santos C, Hamma-Kourbali Y, Burlina F, Delbe J, Chassaing G, Fernig DG, Katsoris P, et al: A basic peptide derived from the HARP C-terminus inhibits anchorage-independent growth of DU145 prostate cancer cells. Exp Cell Res. 2007, 313 (19): 4041-4050. 10.1016/j.yexcr.2007.07.032.CrossRefPubMed
30.
Martel-Renoir D, Trochon-Joseph V, Galaup A, Bouquet C, Griscelli F, Opolon P, Opolon D, Connault E, Mir L, Perricaudet M: Coelectrotransfer to skeletal muscle of three plasmids coding for antiangiogenic factors and regulatory factors of the tetracycline-inducible system: tightly regulated expression, inhibition of transplanted tumor growth, and antimetastatic effect. Mol Ther. 2003, 8 (3): 425-433. 10.1016/S1525-0016(03)00201-6.CrossRefPubMed
31.
Elie N, Plancoulaine B, Signolle JP, Herlin P: A simple way of quantifying immunostained cell nuclei on the whole histologic section. Cytometry A. 2003, 56 (1): 37-45.CrossRefPubMed
32.
Soulie P, Heroult M, Bernard I, Kerros ME, Milhiet PE, Delbe J, Barritault D, Caruelle D, Courty J: Immunoassay for measuring the heparin-binding growth factors HARP and MK in biological fluids. J Immunoassay Immunochem. 2002, 23 (1): 33-48. 10.1081/IAS-120002273.CrossRefPubMed
33.
Diamantopoulou Z, Bermek O, Polykratis A, Hamma-Kourbali Y, Delbe J, Courty J, Katsoris P: A Pleiotrophin C-terminus peptide induces anti-cancer effects through RPTPbeta/zeta. Mol Cancer. 2010, 9: 224-CrossRefPubMedPubMedCentral
34.
Said EA, Courty J, Svab J, Delbe J, Krust B, Hovanessian AG: Pleiotrophin inhibits HIV infection by binding the cell surface-expressed nucleolin. Febs J. 2005, 272 (18): 4646-4659. 10.1111/j.1742-4658.2005.04870.x.CrossRefPubMed
35.
Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E: Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol. 2003, 163 (4): 871-878. 10.1083/jcb.200304132.CrossRefPubMedPubMedCentral
36.
Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R: An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res. 1997, 57 (9): 1814-1819.PubMed
37.
Jager R, Noll K, Havemann K, Knabbe C, Rauvala H, Zugmaier G: Differential expression and biological activity of the heparin-binding growth-associated molecule (HB-GAM) in lung cancer cell lines. Int J Cancer. 1997, 73: 537-543. 10.1002/(SICI)1097-0215(19971114)73:4<537::AID-IJC14>3.0.CO;2-6.CrossRefPubMed
38.
Weber D, Klomp HJ, Czubayko F, Wellstein A, Juhl H: Pleiotrophin can be rate-limiting for pancreatic cancer cell growth. Cancer Res. 2000, 60 (18): 5284-5288.PubMed
39.
Czubayko F, Riegel AT, Wellstein A: Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth. J Biol Chem. 1994, 269 (33): 21358-21363.PubMed
40.
Czubayko F, Schulte AM, Berchem GJ, Wellstein A: Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proceedings of the National Academy of Sciences of the United States of America. 1996, 93 (25): 14753-14758. 10.1073/pnas.93.25.14753.CrossRefPubMedPubMedCentral
41.
Grzelinski M, Urban-Klein B, Martens T, Lamszus K, Bakowsky U, Hobel S, Czubayko F, Aigner A: RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther. 2006, 17 (7): 751-766. 10.1089/hum.2006.17.751.CrossRefPubMed
42.
Foehr ED, Lorente G, Kuo J, Ram R, Nikolich K, Urfer R: Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model. Cancer Res. 2006, 66 (4): 2271-2278. 10.1158/0008-5472.CAN-05-1221.CrossRefPubMed
43.
Ulbricht U, Eckerich C, Fillbrandt R, Westphal M, Lamszus K: RNA interference targeting protein tyrosine phosphatase zeta/receptor-type protein tyrosine phosphatase beta suppresses glioblastoma growth in vitro and in vivo. J Neurochem. 2006, 98 (5): 1497-1506. 10.1111/j.1471-4159.2006.04022.x.CrossRefPubMed
44.
Lu KV, Jong KA, Kim GY, Singh J, Dia EQ, Yoshimoto K, Wang MY, Cloughesy TF, Nelson SF, Mischel PS: Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J Biol Chem. 2005, 280 (29): 26953-26964. 10.1074/jbc.M502614200.CrossRefPubMed
45.
Mathivet T, Mazot P, Vigny M: In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)?. Cell Signal. 2007, 19 (12): 2434-2443. 10.1016/j.cellsig.2007.07.011.CrossRefPubMed
46.
Bowden ET, Stoica GE, Wellstein A: Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. J Biol Chem. 2002, 277 (39): 35862-35868. 10.1074/jbc.M203963200.CrossRefPubMed
47.
Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT, Wellstein A: Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem. 2002, 277 (39): 35990-35998. 10.1074/jbc.M205749200.CrossRefPubMed
48.
Stylianou DC, Auf der Maur A, Kodack DP, Henke RT, Hohn S, Toretsky JA, Riegel AT, Wellstein A: Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor. Oncogene. 2009, 28 (37): 3296-3306. 10.1038/onc.2009.184.CrossRefPubMedPubMedCentral
49.
Ginisty H, Sicard H, Roger B, Bouvet P: Structure and functions of nucleolin. J Cell Sci. 1999, 112 (Pt 6): 761-772.PubMed
50.
Shibata Y, Muramatsu T, Hirai M, Inui T, Kimura T, Saito H, McCormick LM, Bu G, Kadomatsu K: Nuclear targeting by the growth factor midkine. Mol Cell Biol. 2002, 22 (19): 6788-6796. 10.1128/MCB.22.19.6788-6796.2002.CrossRefPubMedPubMedCentral
51.
Take M, Tsutsui J, Obama H, Ozawa M, Nakayama T, Maruyama I, Arima T, Muramatsu T: Identification of nucleolin as a binding protein for midkine (MK) and heparin-binding growth associated molecule (HB-GAM). Journal of Biochemistry. 1994, 116 (5): 1063-1068.PubMed
52.
Destouches D, El Khoury D, Hamma-Kourbali Y, Krust B, Albanese P, Katsoris P, Guichard G, Briand JP, Courty J, Hovanessian AG: Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin. PLoS One. 2008, 3 (6): e2518.-CrossRefPubMedPubMedCentral
53.
Grzelinski M, Steinberg F, Martens T, Czubayko F, Lamszus K, Aigner A: Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia. 2009, 11 (2): 145-156.CrossRefPubMedPubMedCentral
54.
Souttou B, Ahmad S, Riegel AT, Wellstein A: Signal transduction pathways involved in the mitogenic activity of pleiotrophin - Implication of mitogen-activated protein kinase and phosphoinositide 3-kinase pathways. J Biol Chem. 1997, 272 (31): 19588-19593. 10.1074/jbc.272.31.19588.CrossRefPubMed
55.
Dean RA, Butler GS, Hamma-Kourbali Y, Delbe J, Brigstock DR, Courty J, Overall CM: Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/Connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis. Mol Cell Biol. 2007, 27 (24): 8454-8465. 10.1128/MCB.00821-07.CrossRefPubMedPubMedCentral
56.
Polykratis A, Delbe J, Courty J, Papadimitriou E, Katsoris P: Identification of heparin affin regulatory peptide domains with potential role on angiogenesis. Int J Biochem Cell Biol. 2004, 36 (10): 1954-1966. 10.1016/j.biocel.2004.02.012.CrossRefPubMed
Metadata
Title
The synthetic peptide P111-136 derived from the C-terminal domain of heparin affin regulatory peptide inhibits tumour growth of prostate cancer PC-3 cells
Authors
Yamina Hamma-Kourbali
Oya Bermek
Isabelle Bernard-Pierrot
Racha Karaky
Dominique Martel-Renoir
Sophie Frechault
José Courty
Jean Delbé
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-212

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Software

A simple method for assigning genomic grade to individual breast tumours

Research article

c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients

Research article

Exposure to statins and risk of common cancers: a series of nested case-control studies

Research article

Limited importance of the dominant-negative effect of TP53missense mutations

Research article

P53 suppresses expression of the 14-3-3gamma oncogene

Research article

MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits